{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:17:36Z","timestamp":1770743856712,"version":"3.49.0"},"reference-count":38,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"PharmaEssentia Corporation","award":["A20-202"],"award-info":[{"award-number":["A20-202"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.2217\/fon-2022-1141","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T14:54:00Z","timestamp":1683039240000},"page":"753-761","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["A phase II trial to assess the efficacy and safety of ropeginterferon \u03b1-2b in Chinese patients with polycythemia vera"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital,Zhejiang University School of Medicine,\rHangzhou,\rChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-084X","authenticated-orcid":false,"given":"Albert","family":"Qin","sequence":"additional","affiliation":[{"name":"PharmaEssentia Corporation,\rTaipei,\rTaiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College,\rTianjin,\rChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Shen","sequence":"additional","affiliation":[{"name":"PharmaEssentia Biotech (Beijing) Ltd,\rBeijing,\rChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"PharmaEssentia Biotech (Beijing) Ltd,\rBeijing,\rChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[{"name":"PharmaEssentia Biotech (Beijing) Ltd,\rBeijing,\rChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaning","family":"Li","sequence":"additional","affiliation":[{"name":"PharmaEssentia Biotech (Beijing) Ltd,\rBeijing,\rChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoxiang","family":"Wu","sequence":"additional","affiliation":[{"name":"PharmaEssentia Biotech (Beijing) Ltd,\rBeijing,\rChina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College,\rTianjin,\rChina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100714"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26008"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.05.020"},{"key":"e_1_3_6_6_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 1.","year":"2022","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 1. National Comprehensive Cancer Network, PA, USA (2022)."},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-745349"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.4.1288"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208500"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719870052"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-017-0090-5"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0080-6"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.12.69"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01183-8"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01528-x"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15176"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01863-y"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01026-5"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-637280"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118584"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03341-9"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0133-0"},{"key":"e_1_3_6_25_1","volume-title":"FDA Approves Treatment for Rare Blood Disease.","year":"2021","unstructured":"FDA Approves Treatment for Rare Blood Disease. US FDA, MD, USA (2021)."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0596"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14061128"},{"issue":"1","key":"e_1_3_6_28_1","first-page":"343","article-title":"A validated, new-generation PEGylated interferon therapy for chronic hepatitis B and possibly D","volume":"4","author":"Qin A","year":"2022","unstructured":"Qin A , HuangYW, ChenPJ. A validated, new-generation PEGylated interferon therapy for chronic hepatitis B and possibly D. Curr. Trends Gastroenerol. Hepatol.4(1), 343\u2013345 (2022).","journal-title":"Curr. Trends Gastroenerol. Hepatol."},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01998-y"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.08.021"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10098-y"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12613"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.09.018"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12825"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.893310"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.601"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0054-y"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478891"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409002"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30558-7"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-1141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:30Z","timestamp":1719125070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-1141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.2217\/fon-2022-1141"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-1141","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}